Karyopharm Therapeutics (KPTI) Gross Margin (2019 - 2026)

Karyopharm Therapeutics (KPTI) has reported Gross Margin for 7 consecutive years, with 96.75% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin fell 47.0% year-over-year to 96.75%; the trailing twelve-month figure through Jun 2026 stood at 96.16% (down 21.0% YoY), and the FY2025 full-year result was 95.93%, up 6.0% from the prior year.
• Gross Margin rose to 96.75% in Q2 2026 per KPTI's latest filing, from 95.65% in the prior quarter.
• Across five years, Gross Margin topped out at 97.63% in Q2 2022 and bottomed at 94.23% in Q1 2024.
• Historically, Gross Margin has averaged 96.26% across 5 years, with a median of 96.58% in 2024.
• The widest YoY moves for Gross Margin: up 267 bps in 2022, down 498 bps in 2022.
• Over 5 years, Gross Margin stood at 94.44% in 2022, then increased by 1 bps to 95.6% in 2023, then rose by 0 bps to 95.64% in 2024, then increased by 0 bps to 95.65% in 2025, then rose by 1 bps to 96.75% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 96.75%, 95.65%, and 95.2% for Q2 2026, Q4 2025, and Q3 2025 respectively.